#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“While the endocannabinoid system is a legitimate area of neuroscience research, many of the ‘facts’ circulating online about THC lack the human clinical evidence needed to guide patient care, so I encourage people to distinguish between what we know from controlled studies versus what remains fascinating but preliminary neurobiology.”
💊 While educational content about THC’s mechanisms, including its interaction with the endocannabinoid system, can help demystify cannabis for both patients and providers, such public-facing materials often lack the clinical nuance needed for medical decision-making. The endocannabinoid system is indeed relevant to understanding cannabis pharmacology, but isolated “facts” presented without discussion of dose-response relationships, individual variation in metabolism, drug interactions, or long-term safety data may oversimplify a complex pharmacology and inadvertently reinforce assumptions about cannabis safety or efficacy. Healthcare providers should recognize that patient knowledge increasingly comes from diverse online sources, some of which may emphasize cannabis benefits while downplaying risks or acknowledging gaps in evidence. When patients reference such materials during clinical encounters, providers have an opportunity to contextualize this information within established evidence, discuss potential harms alongside mechanisms of action, and clarify what is known versus unknown about clinical
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
